Advanced Search:
Equity Index

GNRO.PA - GENEURO

€1.38  0.08 (6.15%)

Updated: 11:48 May 5, 2024 EST

Next Session's AI Forecast

86.12%

Avg. Accuracy (AI)

€1.25

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

€1.32

GENEURO's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

GENEURO - HISTORICAL DATA 6M

  • Last price

    €1.38

  • Daily change

    €0.08

  • Previous Close

    €1.3

  • Last Updated

    11:48 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.17 0.06 0.62 0.44 -0.1

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.19 1.2 2.22 3.14 2.99

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 100%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
1.48 1.37% 1.46 2.1% 1.43 17.21% 1.22

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
2 -1 1 66.67

GENEURO Technical Analysis News

GENEURO

3 chemin du PrE-Fleuri
Plan-les-Ouates 1228
Switzerland
41 22 552 48 00
https://www.geneuro.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 19
Description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Corporate Governance

GeNeuro SA’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 10.

GENEURO'S HOLDERS RANK

List of holders with stock participation in GENEURO.

Holder Rank Holder Shares Date Reported % Out Value